Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2015
Investors 7
Mentions in press and media 2
| Date | Title | Description |
| 31.10.2023 | Health | CRISPR gene editing could kill HIV. But is it a cure? | In a provocative first step toward an elusive end to a devastating disease that has claimed 40 million lives, three patients have received CRISPR gene-editing therapies in an effort to eradicate HIV from their bodies. The results — whether ... |
| 18.06.2020 | Ben Franklin Approved $1.48M in 7 Early Stage Companies |